Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2321352 | 1.00 | LMNA (0.41) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL2317860 | 1.00 | LMNA (0.41) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL3229856 | 1.00 | LMNA (0.41) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL264710 | 1.00 | LMNA (0.41) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sulfuric Acid SCHEMBL10602546 | 0.98 | LMNA (0.39) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL28503116 | 0.98 | LMNA (0.39) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Methane SCHEMBL17748249 | 0.96 | LMNA (0.38) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL3417631 | 0.84 | LMNA (0.39) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL3415482 | 0.84 | LMNA (0.39) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL3432829 | 0.84 | LMNA (0.39) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130143840-A1 | HEPARAN SULFATE REPLACEMENT THERAPY | AUSTRALIAN NATIONAL UNIVERSITY, THE (AU) | 2013-06-06 | — | — | US | disclosed |
| EP-2550004-A1 | HEPARAN SULFATE REPLACEMENT THERAPY | The Australian National University (AU) | 2013-01-30 | — | — | EP | disclosed |
| WO-2011109877-A1 | HEPARAN SULFATE REPLACEMENT THERAPY | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143840-A1 | HEPARAN SULFATE REPLACEMENT THERAPY | IAPP, HPSE, RNASE1 | LMNA 4089/4885L3MBTL1 3035/4885TDP1 4092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.